An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis

Trial Profile

An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 11 Mar 2017 This trial has been completed in the Czech Republic.
    • 09 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 02 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top